Towards Healthcare
Breast Cancer Liquid Biopsy Market Size Hits USD 795.42 Mn by 2034

Breast Cancer Liquid Biopsy Market Surges in 2025 with AI, Digital PCR & DNA Leading Innovation

Based on market forecasts, the breast cancer liquid biopsy sector will expand from USD 200 million in 2024 to USD 795.42 million by 2034, experiencing a CAGR of 14.8%. Breast cancer cases are rising day by day, which is increasing the demand for biopsy, leading to the significant growth of the breast cancer liquid biopsy market. North America is leading the market due to its advancements in diagnostic procedures.

  • Insight Code: 5883
  • No. of Pages: 150+
  • Format: PDF/PPT/Excel
  • Published: July 2025
  • Report Covered: [Revenue + Volume]
  • Historical Year: 2021-2022
  • Base Year: 2023
  • Estimated Years: 2024-2033

About The Author

Deepa Pandey is a focused and detail-oriented market research professional with growing expertise in the healthcare sector, delivering high-quality insights across therapeutic areas, diagnostics, biotechnology, and healthcare services.

She began her research career at Precedence Research, where she contributed to a wide range of healthcare industry studies, helping build a strong foundation in market intelligence and strategic research. Currently, Deepa plays a critical role at Towards Healthcare, while also extending her research capabilities across Statifacts, supporting cross-industry intelligence initiatives with a focus on healthcare.

Her ability to distill complexity into clarity has made her a trusted contributor to both internal teams and external clients across the healthcare value chain. By combining professionalism with an evolving depth in healthcare research, Deepa consistently adds value to projects that demand critical thinking, market precision, and industry-specific knowledge. Her contributions help organizations navigate the complexities of regulated markets and make data-backed growth decisions.

FAQ's

The breast cancer liquid biopsy market is projected to reach USD 795.42 million by 2034, growing at a CAGR of 14.8% from 2024 to 2034.

North America is currently leading the breast cancer liquid biopsy market due to rising breast cancer cases and growing demand for advancements in liquid biopsy.

The breast cancer liquid biopsy market includes six segments such as by circulating biomarkers, by product & services, by technology, by application, by end-use, and by region.

Key trends include technological advancements, integration of AI and ML, and growing collaboration among key players.

If your current treatment is not working or you have advanced cancer (cancer that has spread or metastasized), a liquid biopsy may be recommended for screening (for certain malignancies in particular patients).

Ministry of Health and Family Welfare, Government of India, National Institutes of Health, FDA, WHO, PIB, CDC.